<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935204</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-PRO-008</org_study_id>
    <nct_id>NCT03935204</nct_id>
  </id_info>
  <brief_title>Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)</brief_title>
  <official_title>An Randomized, Double-Blinded, Placebo Controlled Phase II Clinical Trial to Estimate Immunogenicity of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Adults Aged 18 to 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiamen Innovax Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II clinical study was designed to evaluate the immunogenicity and safety of
      Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter
      called HPV vaccine), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults aged
      18-45 years old.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 (type specific neutralizing antibody)</measure>
    <time_frame>month 7</time_frame>
    <description>To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing antibody level on day 0 (before the 1st dose) and one month after dose 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited local adverse reactions</measure>
    <time_frame>During the 7-day (Day 0-6) period following each vaccination</time_frame>
    <description>Solicited local adverse reactions occurred within 7 days after each vaccination;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited systematic adverse reactions</measure>
    <time_frame>During the 7-day (Day 0-6) period following each vaccination</time_frame>
    <description>Solicited systematic adverse reactions occurred within 7 days after each vaccination;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>Within 30 days (Day 0-29) after any vaccination</time_frame>
    <description>Unsolicited adverse reactions occurred within 30 days after each vaccination;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>throughout the study period, an average of 7 months</time_frame>
    <description>Serious adverse events occurred throughout the study;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 (type specific IgG antibody)</measure>
    <time_frame>month 7</time_frame>
    <description>To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific IgG antibody level on day 0 (before the 1st dose) and one month after dose 3</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations in a immunogenicity subgroup at Months 1,2 and 7 (type specific neutralizing antibody and IgG antibody)</measure>
    <time_frame>month 1,2 and 6</time_frame>
    <description>To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing and IgG antibody level of a immunogenicity subgroup at month 1,2 and 6.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Condylomata Acuminata</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>HPV Vaccine,270μg/1.0ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm would receive 270μg/1.0ml HPV vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm would receive 1.0ml aluminium adjuvant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV Vaccine,270μg/1.0ml</intervention_name>
    <description>HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.</description>
    <arm_group_label>HPV Vaccine,270μg/1.0ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>aluminium adjuvant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Health women aged between 18 and 45 years.

          2. Judged as healthy and eligible for vaccination by the investigators through a
             self-reported medical history and some physical examinations.

          3. Able to comply with the requests of the study.

          4. Written informed consent obtained from the participants.

          5. Axillary temperature not higher than 37.0°C

          6. Non-pregnant women verified by a urine pregnancy test.

        Exclusion Criteria:

          1. Pregnant or breastfeeding or plan to be pregnant within 7 months.

          2. Use of any investigational product or non-registered product (drug or vaccine) within
             30 days preceding the first dose of the study vaccine or plan to use during the study
             period.

          3. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy
             for more than 14 days in the 6 months before entry, except local treatment.

          4. Administration of any immunoglobulin or blood products within 3 months preceding the
             first dose of the study vaccine or plan to use within 7 months.

          5. Administration of any attenuated live vaccines within 21 days preceding the first dose
             of the study vaccine or any subunit or inactivated vaccines within 14 days before
             vaccination.

          6. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring
             systemic antibiotics or antiviral treatment within 5 days before vaccination.

          7. Having the plan to participate another clinical trial during the study period.

          8. Received another HPV vaccine.

          9. Immunodeficiency , primary disease of important organs, malignant tumor, or any immune
             disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or
             functional asplenia or other disease which might affect immune response).

         10. History of allergic disease or history of serious adverse events occurring after
             vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain.

         11. Asthma that required emergent treatment, hospitalization, oral or intravenous
             corticosteroid for unstable condition within the past 2 years.

         12. Having serious disease of internal medicine, such as hypertension, cardiac disease,
             diabetes, hyperthyroidism et al.

         13. Diagnosed coagulant function abnormality or blood coagulation disorder.

         14. Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3
             years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3
             years.

         15. Past or current two-stage affective psychosis, not well controlled in the past 2 years
             or requiring drugs, or hve a tendency to commit suicide in the past 5 years.

         16. Other medical, psychological, social or occupational factors that, according to the
             investigators' judgment, might affect the individual's ability to obey the protocol or
             sign the informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Xiamen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yue-Mei Hu, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Centre for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Provincial Centre for Disease Control and Prevention</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xiamen University</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>human papillomavirus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

